For vaccines to form part of a viable epidemic or pandemic recovery strategy, they must be available quickly and be manufacturable at scale
In line with the requirement for a safe and effective vaccine for global recovery from the crisis, manufacturing of candidate vaccines has already commenced at-risk.
If an effective vaccine against the SARS-CoV-2 virus is developed and approved, it must be produced at sufficient quantity and at the lowest cost possible to have maximum impact at a global scale. In part two of two briefings we will look at how different platform vaccines are manufactured and how adopting flexible manufacturing approaches is likely to have biggest impact on slowing the COVID-19 pandemic, enabling doses of the COVID-19 vaccine to be delivered most rapidly. Technologies to increase manufacturing capacity in low and middle income countries are explored.
This briefing was produced in partnership with UCL STEaPP’s Policy Impact Unit (PIU) as part of the work carried out by the Future Vaccine Manufacturing Research (Vax-Hub). The Vax-Hub is jointly led by UCL and the University of Oxford and funded by the Department of Health and Social Care’s UK Vaccine Network, and managed by the EPSRC.
Professor Martina Micheletti (Department of Biochemical Engineering), Dr Steve Morris (Department of Biochemical Engineering.
Dr Penny Carmichael